# Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

> **NCT02771210** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 204 (actual)

## Conditions studied

- Psoriatic Arthritis
- Axial Spondyloarthritis
- Enthesitis

## Interventions

- **BIOLOGICAL:** Secukinumab
- **DRUG:** Secukinumab Placebo

## Key facts

- **NCT ID:** NCT02771210
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-30
- **Primary completion:** 2019-12-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2021-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02771210

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02771210, "Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02771210. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*